News and Press


First Scientific Publication of eNSAIDs

[1] Kodela R, Chattopadhyay M, and Kashfi K. (2012) NOSH-aspirin: A novel nitric oxide- hydrogen sulfide-releasing hybrid: A new class of anti-inflammatory pharmaceuticals. ACS Med. Chem. Lett. 3, 257–262.
The first scientific publication describing the NOSH platform and eNSAIDs, constiuting a new class of anti-inflammatory drugs appeared in the American Chemical Society Journal 'Medicinal Chemistry Letters'  in 2012 [1]  [ link ].
Recognizing the importance of the publication, the American Chemical Society featured the article in its weekly news PressPak [ link ]. 
Due to the ubiquitous nature of NSAIDs and the simple yet elegant approach to eNSAIDs, this Medicinal Chemistry Letters publication generated a lot of interest in the scientific and broader communities worldwide. A selection of these news stories, with links to the original articles, where possible, are presented below.
Articles describing the new 'Super Aspirin' appeared in the Telegraph, Daily Mail, and the Express,  major UK newspapers, shortly after the Medicinal Chemistry Letters paper was published. These articles  described the the NOSH platform and the discovery and properties of eNSAIDs, NOSH-Aspirin (NBS-1120) in particular. Please click on the  images to access the articles.

Articles on the NOSH platform and eNSAIDs also appeared in broader international news media, in particular in the Middle East. Articles appeared in English in Azerbaijan [ link ] and Iran [ link ], and in Arabic in Iran [ link , link ]. Additional non-English articles can be downloaded here: 
Download
Science & U! is an accessible YouTube channel for all ages that explores the world of science,  highlighting the everyday importance of new discoveries. Here, reporter Ernabel DeMillo looks at the dangers behind over the counter NSAID pain medication and tells us about research being done on a "super" aspirin, NBS-1120. Dr Kasfi explains the mechanism and potential applications of eNSAIDs.
Enhanced NSAIDs explained
"Super Aspirin" in the news
Click on the images to view the articles

International Science Magazines

Click on the image to view the article
Click on the image to view the article
The ACS Medicinal Chemistry Letters inspired articles in international science magazines. New Scientist, a UK  based publication, contrasted the anti-cancer activity of NBS-1120 with Aspirin itself, highlighting the potential serious complications of long term dosing with Aspirin and referred to  another scientific publication by Dr Kasfi that focused on the anticancer activity, mechanism of action and animal safety profile of NBS-1120 that appeared in Biochemical and Biophysical Research Communications [ link ].
The article in Science Daily reported that NBS-1120 demonstrated 250,000 times greater potency than aspirin alone in cultured cancer cells 72 hours after dosing.  The article also highlighted that NBS-1120 activity was 15,000 times greater than existing NO-aspirins and 80-fold more than those that incorporate H2S, suggesting that the activity of NBS-1120 is greater than the sum of its parts. 
The News Medical International article highlighted the activity of NBS-1120 in various cancer cell lines: The cancers controlled included colon, pancreatic, lung, prostate, breast, and leukemia. "The key components of this new compound are that it is very, very potent and yet it has minimal toxicity to the cells," said Associate Professor Khosrow Kashfi, the principal investigator.
Click on the image to view the article